Evidence map›Paper›PMID 41260511›Full record

ArticleCancer letters2026

CD40 drives tumor growth in non-small cell lung cancer via non-canonical immune-independent mechanisms.

Yujie Liu, Chandra Bhushan Prasad, Zhaojun Qiu, Deepika Singh, Nicholas Bean, Shravya Honne, Xiaoli Zhang, Chunhong Yan, Zaibo Li, Baek Kim and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yujie LiuDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center and College of Medicine, Columbus, OH, 43210, United States. Electronic address: liuyujieserena@gmail.com.
Chandra Bhushan PrasadDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center and College of Medicine, Columbus, OH, 43210, United States. Electronic address: Chandra.prasad@osumc.edu.
Zhaojun QiuDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center and College of Medicine, Columbus, OH, 43210, United States. Electronic address: Zhaojun.qiu@osumc.edu.
Deepika SinghDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center and College of Medicine, Columbus, OH, 43210, United States. Electronic address: deepikasingh.bhu05@gmail.com.
Nicholas BeanDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center and College of Medicine, Columbus, OH, 43210, United States. Electronic address: bean.331@buckeyemail.osu.edu.
Shravya HonneDepartment of Pediatrics, School of Medicine Emory University, Atlanta, GA, 30322, United States. Electronic address: honneshravya@gmail.com.
Xiaoli ZhangUSF Health, University of South Florida, Tampa, FL, 33612, United States. Electronic address: xiaoli18@usf.edu.
Chunhong YanGeorgia Cancer Center, Augusta University Medical College, 1410 Laney Walker Blvd., CN-2134, Augusta, GA, 30912, United States. Electronic address: CYAN@augusta.edu.
Zaibo LiDepartment of Pathology, College of Medicine, The Ohio State University, Columbus, OH, 43210, United States. Electronic address: Zaibo.li@osumc.edu.
Baek KimDepartment of Pediatrics, School of Medicine Emory University, Atlanta, GA, 30322, United States. Electronic address: baek.kim@emory.edu.
Qi-En WangDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center and College of Medicine, Columbus, OH, 43210, United States. Electronic address: Qi-En.Wang@osumc.edu.
Junran ZhangDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center and College of Medicine, Columbus, OH, 43210, United States; Center for Metabolism, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, United States; Pelotonia Institute for Immuno-Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, United States. Electronic address: Junran.zhang@osumc.edu.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
Lentivirus Replication Strategy and PathogenesisR01AI136581 · NIAID · EMORY UNIVERSITY · PI Baek Kim · 2018 to 2026
$3.9M
SAMHD1 mediated dNTP regulation and HIV in myeloid cellsR01AI162633 · NIAID · EMORY UNIVERSITY · PI Baek Kim · 2021 to 2026
$2.7M
Targeting cholesterol metabolism and replication stress response in cancer therapyR01CA249198 · NCI · OHIO STATE UNIVERSITY · PI ZHANG, JUNRAN · 2021 to 2025
$1.8M
B55 alpha deficiency as a therapeutic target in cancerR01CA240374 · NCI · OHIO STATE UNIVERSITY · PI ZHANG, JUNRAN · 2020 to 2024
$1.6M
Exploring potential biomarkers predictive of response to ATR and CHK1 inhibitorsR21CA226317 · NCI · OHIO STATE UNIVERSITY · PI ZHANG, JUNRAN · 2018 to 2019
$367k
NCATS NIH HHS UL1 TR002733NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA240374NCI NIH HHS R01 CA249198NCI NIH HHS R21 CA226317NIAID NIH HHS R01 AI136581NIAID NIH HHS R01 AI162633
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41260511
PMCPMC12750971

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.